Brought to you by 
Vesta buys Incara's liver cell program assets
05 Nov 2002
Executive Summary
Vesta Therapeutics bought all the assets and liabilities of the liver cell and stem cell programs from Incara Pharmaceuticals' wholly owned subsidiary Incara Cell Technologies (formerly Renaissance Cell Technologies).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vesta buys Incara's liver cell program assets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice